All the above results indicate that ZFHX3 mutation can be regarded as a valuable predictive biomarker for immunotherapy in NSCLC, and it shows a positive therapeutic effect, especially for LUAD patients with ZFHX3 and TP53 co-mutation. This evidence concerns the gene TP53 and non-small cell lung carcinoma.